Generated by AI
Innoviva Inc. is a diversified biopharmaceutical company focused on healthcare assets, royalty streams, and specialty therapeutics. Its core business includes a royalty portfolio tied to respiratory medicines partnered with GSK, along with ownership and management of operating healthcare businesses. Through Innoviva Specialty Therapeutics, the company develops and commercializes treatments in critical care and infectious disease, including antimicrobial and hospital-focused therapies. Innoviva also maintains strategic investments in healthcare assets and related life sciences businesses, giving it a broader role across drug development, licensing, and asset management. Headquartered in Burlingame, California, Innoviva Inc. combines recurring royalty income with product-focused operations, positioning it as a multi-asset participant in the biopharmaceutical market.
Website1350 Old Bayshore Highway
Burlingame, CA, 94010
United States
The latest articles about INVA.
Summary of Mar 5's posts. Generated by AI.
No summary yet.
Summary of Apr 3's posts. Generated by AI.
BURLINGAME, Calif., November 04, 2026--Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (IST), and a portfolio of strategic investments in healthcare assets, today reported financial results for the third quarter ended September 30, 2026, and highlighted select corporate progress and achievements.
Summary of Apr 18's posts. Generated by AI.
Investors talking about INVA also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.